A Blockbuster Finish: Molbio Diagnostics IPO Closes with a Massive 43.07x Subscription on Final Day
Molbio Diagnostics Limited is subscribed 43.07 times overall on day 3 of bidding, with QIB 109x, NII 35.35x, retail 9.08x. Figures are official exchange data. Subscription measures demand for the issue, not how it will list.
A Blockbuster Finish: Molbio Diagnostics IPO Closes with a Massive 43.07x Subscription on Final Day
The initial public offering (IPO) of Molbio Diagnostics Limited wrapped up its bidding process on a spectacularly high note. Closing on Wednesday, August 12, 2026, the ₹939.70-crore mainboard IPO attracted phenomenal interest from all categories of investors, resulting in a massive final subscription of 43.07 times on Day 3.
Final Day Subscription Frenzy The highly anticipated healthcare IPO witnessed a tsunami of bids in the closing hours. Institutional buyers and high-net-worth individuals aggressively backed the issue, cementing overwhelming market confidence in the company’s business model and growth prospects. Retail investors, tracking the solid Grey Market Premium (GMP) and the company’s robust financials, also turned up in huge numbers, contributing to the blockbuster finale.
Key Highlights of the Molbio Diagnostics IPO For investors tracking this major primary market event, here is a quick overview of the offering: Total Issue Size:* ₹939.70 crore. Offer Structure:* A fresh issue of equity shares worth ₹200 crore, coupled with an Offer for Sale (OFS) of ₹739.70 crore (91,66,000 equity shares) by selling shareholders. Price Band:* ₹768 to ₹807 per equity share. Lot Size:* Minimum bid of 18 shares, requiring an upfront investment of ₹14,526 at the upper price band. Fund Utilization:* The ₹200 crore raised via the fresh issue is allocated for setting up an R&D facility and Centre of Excellence (₹125.12 crore), alongside capital expenditure for plant and machinery across its Goa and Visakhapatnam units (₹80.81 crore).
Revolutionizing Healthcare: The Truenat Advantage Molbio Diagnostics has established itself as a pioneer in point-of-care (POC) molecular diagnostics. The company is globally renowned for its proprietary Truenat platform—a portable, battery-operated, real-time PCR testing system capable of delivering accurate results within an hour.
Designed specifically for resource-limited settings, Truenat offers over 43 diagnostic assays across more than 30 diseases, including Tuberculosis (TB), COVID-19, HIV, and Hepatitis. With backing from global health organizations and a strong footprint in government public healthcare programs, Molbio Diagnostics stands out as a unique, R&D-focused innovator in the rapidly expanding diagnostics space.
What’s Next: Allotment and Listing With the subscription window now officially closed at an impressive 43.07x, the focus shifts to the share allotment process.
The basis of allotment is expected to be finalized on Thursday, August 13, 2026. Refunds for unsuccessful bidders and the crediting of shares to the demat accounts of lucky allottees are scheduled for Friday, August 14, 2026.
Finally, the equity shares of Molbio Diagnostics are poised to make their grand debut on Dalal Street, with listings on both the BSE and NSE scheduled for Monday, August 17, 2026. Given the spectacular subscription numbers and the company’s cutting-edge healthcare technology, the market is highly optimistic about a strong listing debut.